OM Pharma
OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.
OM Pharma was established in Barcelona in 1930 and relocated its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard, a French pharmacist. In 2020, the company became part of Optimus Holding, led by Etienne Jornod.
The company specializes in developing and commercializing bacterial lysate-based products designed to help prevent respiratory and urinary tract infections by enhancing the immune system. Its research pipeline includes future applications of lysates.
In 2021, OM Pharma received the Geneva Economy Award.
History
Integration into CSL Vifor/Galenica
In 1970, OM Pharma relocated its main operations to Meyrin, where the company continues to operate. In 2009, it was acquired by Galenica, a part of the Vifor Pharma Group.Acquisition by Optimus Holding
In 2020, OM Pharma was acquired by Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod with a consortium of inverstors. As part of the transaction, Optimus Holding committed to investing over CHF 250 million to enhance the company’s manufacturing and research capabilities. Since 2024, Roch Ogier has served as the company’s CEO.Structure and subsidiaries
OM Pharma employs over 400 people, with its global headquarters and biotech campus located in Meyrin, Geneva, and an affiliate in Villars-sur-Glâne, Fribourg.The company also operates in Peru through an affiliate in Lima and maintains a sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic.